Microvast Holdings announces departure of chief financial officer
On Tuesday, UnitedHealth Group (NYSE:UNH) shares may face pressure following the announcement of a change in leadership and the suspension of its 2025 guidance. Morgan Stanley (NYSE:MS) analysts reiterated their Overweight rating and a price target of $563.00 on the healthcare giant’s stock, which is currently trading near its 52-week low of $376.83. According to InvestingPro data, the stock’s RSI suggests oversold conditions, potentially presenting an opportunity for value investors.
UnitedHealth Group informed stakeholders that Sir Andrew Witty would be stepping down as CEO due to personal reasons. Stephen Hemsley, who previously led the company from 2006 to 2017, will take over the role with immediate effect. The transition comes after recent discussions about leadership had intensified. Despite the leadership change, UnitedHealth maintains strong fundamentals with a P/E ratio of 15.75 and a market capitalization of $343.58 billion.
In conjunction with the leadership change, UnitedHealth also announced the suspension of its 2025 guidance. The company cited an increase in care activity and challenges with the new member mix in Medicare Advantage as factors for the adjustment. This update is part of a series of challenges the company has faced, with investor attention likely to shift toward the ongoing elevated cost trends, which are exceeding expectations. InvestingPro analysis shows 20 analysts have revised their earnings downward for the upcoming period, though the company maintains a strong financial health score.
The company’s cost trends are not only related to Group Medicare Advantage but have also expanded to other benefit offerings, a situation that may also impact shares of peer companies as the market awaits confirmation on whether this is an isolated issue or indicative of a broader trend.
UnitedHealth Group is aiming for a ’return to growth in 2026’, adjusting from the previous 2025 earnings per share guidance of a 5% decrease at market performance. A conference call was scheduled for Tuesday morning at 8 am ET to discuss these developments. The webcast details were provided for those interested in the announcements.
In other recent news, UnitedHealth Group’s earnings and revenue performance has been under scrutiny by several analyst firms. Bernstein SocGen Group lowered UnitedHealth’s stock target to $594 from $703, citing a slight miss in earnings per share (EPS) and revenue expectations, with the adjusted EPS reported at $7.20 and revenue at $109.6 billion. RBC Capital Markets also reduced its price target to $525 from $655, noting that UnitedHealth’s first-quarter performance did not meet expectations due to lower engagement of new Optum Health members and higher Medicare Advantage utilization rates. TD Cowen revised its price target to $520, reflecting a more conservative outlook due to challenges such as unexpected Medicare Advantage unit trends and lower coded membership in Optum Health.
Jefferies adjusted its price target to $530, maintaining a Buy rating, while acknowledging operational setbacks in UnitedHealth’s Medicare Advantage segment. Piper Sandler, however, maintained an Overweight rating with a $552 price target, expressing optimism about the CEO transition with Stephen Hemsley returning. Piper Sandler highlighted the strategic importance of repricing at UnitedHealthcare and standardized care delivery practices at Optum Health. UnitedHealth has suspended its CY25 guidance but plans to resume growth in CY26. These developments reflect the varied analyst perspectives on UnitedHealth’s current challenges and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.